Delving into the Latest Updates on HRL1101 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

HRL1101

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Hyperphosphatemia

Inactive Indication-

Originator Organization

Beijing Huarui Dingxin Technology Co., Ltd

Hunan Zhengtai Jinhu Pharmaceutical Co. Ltd.

Active Organization

Hunan Zhengtai Jinhu Pharmaceutical Co. Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价在健康参与者中单次、多次口服HRL1101散后的安全性、耐受性。次要目的： 1. 评价在健康参与者中单次、多次口服HRL1101散后的药代动力学特征； 2. 探索健康参与者单次口服HRL1101散后的代谢与排泄特征； 3. 评价在健康参与者中单次、多次口服HRL1101散后的药效动力学特征。

[Translation]

Primary Objective: To evaluate the safety and tolerability of HRL1101 powder after single and multiple oral administrations in healthy participants. Secondary Objectives: 1. To evaluate the pharmacokinetic characteristics of HRL1101 powder after single and multiple oral administrations in healthy participants; 2. To explore the metabolic and excretion characteristics of HRL1101 powder after a single oral administration in healthy participants; 3. To evaluate the pharmacodynamic and pharmacokinetic characteristics of HRL1101 powder after single and multiple oral administrations in healthy participants.

Start Date-

Sponsor / Collaborator

Hunan Zhengtai Jinhu Pharmaceutical Co. Ltd.

[+1]

100 Clinical Results associated with HRL1101

Login to view more data

100 Translational Medicine associated with HRL1101

Login to view more data

100 Patents (Medical) associated with HRL1101

Login to view more data

100 Deals associated with HRL1101

Login to view more data